Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 8:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HIV Lipodystrophy Syndrome Clear all
Completed No phase listed Observational

Perceived Changes in Body Build and Image in Patients Who Are Now Taking or Recently Have Stopped Taking Anti-HIV Drugs

NCT00006290
View directory record Official record
Conditions
HIV Infections, Lipodystrophy
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
San Diego, California • Baltimore, Maryland • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2008 · Synced Sep 27, 2026, 8:48 AM EDT
Completed Phase 1 Interventional

Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome

NCT00006185
View directory record Official record
Conditions
HIV Infections, Lipodystrophy, Insulin Resistance
Interventions
Avandia administration for 6-12 weeks
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2010 · Synced Sep 27, 2026, 8:48 AM EDT
Not listed Not applicable Interventional

Pilot Study of Raltegravir Lipodystrophy IISP

NCT01164605
View directory record Official record
Conditions
HIV Infection
Interventions
Raltegravir
Drug
Lead sponsor
Southern California Institute for Research and Education
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated May 17, 2012 · Synced Sep 27, 2026, 8:48 AM EDT
Completed Phase 3 Interventional

TH9507 in Patients With HIV-Associated Lipodystrophy

NCT00123253
View directory record Official record
Conditions
HIV Infections, Lipodystrophy
Interventions
TH9507
Drug
Lead sponsor
Theratechnologies
Industry
Eligibility
18 Years to 65 Years
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
35
States / cities
Los Angeles, California • Palm Springs, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2013 · Synced Sep 27, 2026, 8:48 AM EDT
Terminated Phase 4 Interventional Results available

Switching From Efavirenz to Atazanavir/ Ritonavir in HIV-infected Subjects With Good Virologic Suppression

NCT01194856
View directory record Official record
Conditions
HIV Infection, Mitochondrial Dysfunction
Interventions
Atazanavir/ritonavir, Efavirenz
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Sep 27, 2026, 8:48 AM EDT
Completed Phase 2 Interventional

Changing to Nonprotease Inhibitor Treatment to Improve Side Effects

NCT00021463
View directory record Official record
Conditions
HIV Infections, Lipodystrophy
Interventions
Abacavir sulfate, Lamivudine and Zidovudine, Abacavir sulfate, Efavirenz, Nevirapine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
11
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2011 · Synced Sep 27, 2026, 8:48 AM EDT
Completed Phase 4 Interventional

Contribution of Dolutegravir to Obesity and Cardiovascular Disease

NCT04340388
View directory record Official record
Conditions
HIV-1-infection, Antiviral Drug Adverse Reaction, Vascular Diseases, Cardiovascular Abnormalities, Abnormality of Adipose Tissue, Body Weight Changes, Body Fat Disorder, HIV-Associated Lipodystrophy Syndrome
Interventions
Dolutegravir 50 MG, Antiretroviral/Anti HIV
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 27, 2026, 8:48 AM EDT
Completed No phase listed Observational

Facial Lipoatrophy Correction Experience With SCULPTRA ("FACES" Study)

NCT00360932
View directory record Official record
Conditions
Facial Lipoatrophy
Interventions
SCULPTRA (poly-L-lactic acid injection)
Device
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Sep 27, 2026, 8:48 AM EDT
Completed No phase listed Observational Results available

Metabolic Effects of Non-Thymidine Analogue Anti-HIV Medications

NCT00433992
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2017 · Synced Sep 27, 2026, 8:48 AM EDT
Completed No phase listed Observational

Growth Hormone Dynamics and Cardiac Steatosis in HIV

NCT03826160
View directory record Official record
Conditions
Human Immunodeficiency Virus, Lipodystrophy, Cardiac Disease
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 70 Years
Enrollment
23 participants
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Sep 27, 2026, 8:48 AM EDT
Withdrawn No phase listed Observational

Egrifta Replacement and Sleep Disordered Breathing

NCT01788462
View directory record Official record
Conditions
Lipodystrophy
Interventions
Tesamorelin (Egrifta)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 27, 2026, 8:48 AM EDT
Completed No phase listed Observational

SNAP: Switching Nucleoside Analogues Protocol - Lipoatrophy and Mitochondrial Function

NCT00225082
View directory record Official record
Conditions
HIV Infection
Interventions
Nucleoside analogue switch
Drug
Lead sponsor
Northwestern University
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 4, 2010 · Synced Sep 27, 2026, 8:48 AM EDT
Completed Phase 3 Interventional

Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids

NCT00006412
View directory record Official record
Conditions
HIV Infections, Lipodystrophy
Interventions
Pravastatin sodium, Fenofibrate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2003
U.S. locations
57
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 27, 2026, 8:48 AM EDT
Recruiting No phase listed Observational

The LD Lync Study - Natural History Study of Lipodystrophy Syndromes

NCT03087253
View directory record Official record
Conditions
Lipodystrophy (Genetic or Acquired, Non HIV)
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2034
U.S. locations
2
States / cities
Bethesda, Maryland • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Sep 27, 2026, 8:48 AM EDT
Completed Not applicable Interventional Results available

Exercise and Pioglitazone for HIV-Metabolic Syndromes

NCT00639457
View directory record Official record
Conditions
HIV Infections, Type 2 Diabetes, Obesity, HIV, AIDS, Cardiovascular Disease, Lipodystrophy
Interventions
Pioglitazone, Exercise training
Drug · Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 22, 2013 · Synced Sep 27, 2026, 8:48 AM EDT
Terminated Phase 4 Interventional Results available

Body Composition and Adipose Tissue in HIV

NCT03226821
View directory record Official record
Conditions
HIV Lipodystrophy Syndrome, Growth Hormone Deficiency, Body Composition
Interventions
Tesamorelin
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 68 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 27, 2026, 8:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs

NCT00017758
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity, Lipodystrophy
Interventions
Pravastatin sodium, Simvastatin, Atorvastatin calcium, Nelfinavir mesylate, Efavirenz
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
10
States / cities
Stanford, California • Denver, Colorado • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2006 · Synced Sep 27, 2026, 8:48 AM EDT
Completed Phase 4 Interventional Results available

Study of Reyataz in HIV-infected Patients With Lipodystrophy Syndrome

NCT00135356
View directory record Official record
Conditions
HIV-Associated Lipodystrophy Syndrome
Interventions
Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs), continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
4
States / cities
Fort Lauderdale, Florida • Honolulu, Hawaii • Huntersville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2010 · Synced Sep 27, 2026, 8:48 AM EDT
Completed No phase listed Observational

Long-Term Data Collection From Participants in Adult AIDS Clinical Trials

NCT00001137
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
13 Years and older
Enrollment
5,982 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
75
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 46 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2013 · Synced Sep 27, 2026, 8:48 AM EDT
Not listed Phase 4 Interventional

SHARE: Simple HAART With Abacavir, Reyataz, and Epivir

NCT00426296
View directory record Official record
Conditions
HIV Infections, Lipodystrophy
Interventions
atazanavir (Reyataz), ritonavir (Norvir)
Drug
Lead sponsor
Clinical Alliance for Research & Education - Infectious Diseases, LLC.
Other
Eligibility
18 Years and older
Timeline
Started 2006
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 31, 2007 · Synced Sep 27, 2026, 8:48 AM EDT
Completed No phase listed Observational

Evaluation of Albuminuria HIV-Infected Patients

NCT00524992
View directory record Official record
Conditions
HIV-Associated Focal Segmental Glomerulosclerosis, HIV-Associated Collapsing Glomerulopathy, Proteinuria, Albuminuria, Renal Tubular Toxicity
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Sep 27, 2026, 8:48 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients

NCT00082628
View directory record Official record
Conditions
HIV Infections, Lipodystrophy
Interventions
Placebo, Serostim® 4 mg, Serostim® 2 mg
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 60 Years
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
30
States / cities
Birmingham, Alabama • Los Angeles, California • Palm Springs, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Sep 27, 2026, 8:48 AM EDT
Completed Phase 4 Interventional

A Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients

NCT00005106
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine/Zidovudine, Abacavir sulfate, Nelfinavir mesylate, Lamivudine, Stavudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
39
States / cities
Birmingham, Alabama • Tucson, Arizona • Longbeach, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 27, 2026, 8:48 AM EDT
Completed Not applicable Interventional Results available

Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome

NCT00656851
View directory record Official record
Conditions
HIV Infections, Cardiovascular Disease, Insulin Resistance, HIV Lipodystrophy, The Metabolic Syndrome
Interventions
Pioglitazone, Exercise Training
Drug · Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
28 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 27, 2013 · Synced Sep 27, 2026, 8:48 AM EDT